BOSTON-A frequent problem with abdominal surgery is afterward, the digestive system has a tendency to shut down for several days. This extends a patient's recovery time, increasing healthcare costs and the time demanded on the hospital per patient.
A new analgesic created in the labs of the biopharmaceutical company Adolor Corp., may reduce both the cost and recovery time associated with abdominal surgery by helping the digestive tract function properly.
ADL 8-2698 is a new opioid antagonist that reportedly does not cross the blood-brain barrier, meaning the drug can relieve pain during recovery. Pharmaceuticals usually given during abdominal surgeries, including morphine and other opium-based painkillers, tend to aggravate the digestive tract. Because ADL 8-2698 is an opioid antagonist-a synthetic narcotic not derived from opium, the condition does not occur.
A trial of the drug was conducted on 79 patients who were set to undergo hysterectomies or partial removal of the colon. With surgery being cancelled for one patient, the group was left with 15 undergoing partial colectomies and 63 having total abdominal hysterectomies. The group was randomly split and given either the drug or a placebo.
The ADL 8-2698 group received one capsule 2 hours before their surgery and then one twice daily after surgery until they had their first bowel movement. These patients had a significantly faster recovery time of 70 hours compared to those patients who received a placebo. The placebo group recovered on average after 111 hours.
The opioid antagonist had been tested previously to control the pain of patients undergoing other procedures, but this was the first study examining the affects of the drug on abdominal surgeries.
For more information about Exton, Pa based Adolor Corp., log onto: www.adolor.com
Information from www.givenimaging.com, Reuters Health
The Hidden Dangers of Hospital Ventilation: Are We Spreading Viruses Further?
January 31st 2025New research reveals hospital ventilation and air purifiers may unintentionally spread viral particles, increasing infection risks. Infection preventionists must rethink airflow strategies to protect patients and staff.
Alcohol-Based Antiseptics Show Promise for Nasal Decolonization and SSI Prevention
January 23rd 2025A meta-analysis found alcohol-based antiseptics significantly reduce Staphylococcus aureus-related surgical site infections (SSIs), demonstrating efficacy comparable to mupirocin and iodophor, supporting their expanded use in infection prevention strategies.
Top 7 Infection Control Today Articles of 2024: Insights and Innovations
December 30th 2024From advanced sterilization methods to combating antimicrobial resistance, Infection Control Today’s top articles of 2024 delivered actionable strategies for safer healthcare environments and improved patient outcomes.
Understanding NHSN's 2022 Rebaseline Data: Key Updates and Implications for HAI Reporting
December 13th 2024Discover how the NHSN 2022 Rebaseline initiative updates health care-associated infection metrics to align with modern health care trends, enabling improved infection prevention strategies and patient safety outcomes.
Tackling Health Care-Associated Infections: SHEA’s Bold 10-Year Research Plan to Save Lives
December 12th 2024Discover SHEA's visionary 10-year plan to reduce HAIs by advancing infection prevention strategies, understanding transmission, and improving diagnostic practices for better patient outcomes.